Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 315,522 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the transaction, the chief operating officer now owns 959,457 shares in the company, valued at approximately $10,611,594.42. This trade represents a 24.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total value of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.

Roivant Sciences Trading Up 0.4 %

Shares of ROIV opened at $10.83 on Tuesday. The firm’s 50-day moving average is $10.79 and its two-hundred day moving average is $11.45. Roivant Sciences Ltd. has a twelve month low of $9.93 and a twelve month high of $13.06. The firm has a market capitalization of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ROIV. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $18.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. Norges Bank acquired a new position in Roivant Sciences during the fourth quarter worth about $52,443,000. TOMS Capital Investment Management LP acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $46,333,000. Invesco Ltd. increased its stake in shares of Roivant Sciences by 49.7% during the 4th quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after purchasing an additional 3,159,603 shares in the last quarter. FMR LLC raised its position in shares of Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.